Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
Primary Care
What is your approach to de-escalation of asthma therapy if patients have remained clinically stable on triple inhaler therapy and a biologic agent?
Answer from: at Community Practice
Since the reason most folks need biologics is prednisone and considering the side effects, getting patients down to the lowest dose is beneficial.
Sign In
or
Register
to read more
23325
Related Questions
How do you manage persistent pseudomonas positive sputum a patient with non-CF bronchiectasis who has chronic sputum production but is otherwise asymptomatic?
Do you implement FEV3/FEV6 or FEF25-75 measurements in the evaluation of patients for small airways obstruction?
How do you manage daytime somnolence without a clear cause?
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
How do you counsel patients who are concerned that discontinuation of certain chronic medications may actually perpetuate suffering at the end of life?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
How do you consider sending fungal studies in a patient with pneumonia?
Is there an upper threshold of pCO₂ that can cause symptomatic hypercapnia (e.g. AMS) despite metabolic compensation and normal pH?
When do you consider switching from another biologic to benralizumab in patients with severe eosinophilic asthma with a history of suboptimal response to previous biologic agents?
What is your next step in treatment for tobacco use disorder for a patient who continues to smoke after 12 weeks of therapy with varenicline?